BR112015024621A8 - usos de dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica compreendendo a referida dose unitária, kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano e dose unitária de unidades formadoras de colônia de c. novyi - Google Patents

usos de dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica compreendendo a referida dose unitária, kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano e dose unitária de unidades formadoras de colônia de c. novyi Download PDF

Info

Publication number
BR112015024621A8
BR112015024621A8 BR112015024621A BR112015024621A BR112015024621A8 BR 112015024621 A8 BR112015024621 A8 BR 112015024621A8 BR 112015024621 A BR112015024621 A BR 112015024621A BR 112015024621 A BR112015024621 A BR 112015024621A BR 112015024621 A8 BR112015024621 A8 BR 112015024621A8
Authority
BR
Brazil
Prior art keywords
novyi
unit dose
human
solid tumor
treating
Prior art date
Application number
BR112015024621A
Other languages
English (en)
Other versions
BR112015024621A2 (pt
BR112015024621B1 (pt
Inventor
Vogelstein Bert
W Kinzler Kenneth
Saha Saurabh
Zhou Shibin
Original Assignee
Biomed Valley Discoveries Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Valley Discoveries Inc, Univ Johns Hopkins filed Critical Biomed Valley Discoveries Inc
Priority to BR122020006408-0A priority Critical patent/BR122020006408B1/pt
Publication of BR112015024621A2 publication Critical patent/BR112015024621A2/pt
Publication of BR112015024621A8 publication Critical patent/BR112015024621A8/pt
Publication of BR112015024621B1 publication Critical patent/BR112015024621B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

"c. novyi para o tratamento de tumores sólidos em seres humanos". a presente invenção proporciona, inter alia, métodos para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano. esses métodos incluem administrar de modo intratumoral ao ser humano uma dose de unidade de unidades formadoras de colônias (cfus) de c. novyi, preferivelmente c. novyi nt, que contém cerca de 1 x 103-1 x 107 cfus suspensa em um veículo ou solução farmaceuticamente aceitável. são também proporcionados métodos para diminuir o volume de um tumor sólido presente em um ser humano, métodos para remover um tumor sólido presente em um ser humano, um método para a excisão microscopicamente exata de células de tumor em um ser humano, métodos para tratar ou atenuar um efeito de um tumor sólido que tenha se espalhado por metástase para um ou mais locais em um ser humano, doses de unidades de cfus de c. novyi, preferivelmente c. novyi nt, e kits para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano.
BR112015024621-4A 2013-03-29 2014-03-28 Usos de dose unitária de unidades formadoras de colônia de c. novyi e de dose unitária de esporos de c. novyi nt e kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano BR112015024621B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020006408-0A BR122020006408B1 (pt) 2013-03-29 2014-03-28 Dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica e uso de c. novyi nt para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361806497P 2013-03-29 2013-03-29
US61/806,497 2013-03-29
PCT/US2014/032196 WO2014160950A1 (en) 2013-03-29 2014-03-28 C. novyi for the treatment of solid tumors in humans

Publications (3)

Publication Number Publication Date
BR112015024621A2 BR112015024621A2 (pt) 2017-07-18
BR112015024621A8 true BR112015024621A8 (pt) 2019-12-10
BR112015024621B1 BR112015024621B1 (pt) 2021-09-28

Family

ID=51625539

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122020006408-0A BR122020006408B1 (pt) 2013-03-29 2014-03-28 Dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica e uso de c. novyi nt para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano
BR112015024621-4A BR112015024621B1 (pt) 2013-03-29 2014-03-28 Usos de dose unitária de unidades formadoras de colônia de c. novyi e de dose unitária de esporos de c. novyi nt e kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122020006408-0A BR122020006408B1 (pt) 2013-03-29 2014-03-28 Dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica e uso de c. novyi nt para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano

Country Status (20)

Country Link
US (3) US10617723B2 (pt)
EP (3) EP3730146B1 (pt)
JP (6) JP6756609B2 (pt)
KR (1) KR20160021084A (pt)
CN (2) CN116570628A (pt)
AU (2) AU2014240872A1 (pt)
BR (2) BR122020006408B1 (pt)
CA (2) CA3206655A1 (pt)
DK (1) DK2988760T3 (pt)
ES (2) ES2815564T3 (pt)
HK (1) HK1222134A1 (pt)
IL (1) IL241823B (pt)
MX (1) MX2015013784A (pt)
NZ (1) NZ712691A (pt)
PH (1) PH12015502260A1 (pt)
RU (1) RU2718670C2 (pt)
SG (2) SG10201902765VA (pt)
UA (1) UA120036C2 (pt)
WO (1) WO2014160950A1 (pt)
ZA (2) ZA201507412B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6712952B2 (ja) * 2014-03-31 2020-06-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 固形腫瘍悪性病変を処置するための、抗ｃｔｌａ−４抗体および／または抗ｐｄ−１抗体と組み合わせた、細菌、細菌産物、および他の免疫調節性実体の使用
CN105912930B (zh) * 2016-04-11 2019-02-01 北京奇虎科技有限公司 移动终端及其系统资源安全控制方法
WO2018039185A1 (en) * 2016-08-23 2018-03-01 Mayo Foundation For Medical Education And Research Methods and materials for treating estrogen receptor positive breast cancer
CN116036278A (zh) * 2017-05-16 2023-05-02 生物医学谷探索股份有限公司 用于治疗具有非典型braf突变的癌症的组合物和方法
CN109985039A (zh) * 2017-12-29 2019-07-09 深圳微芯生物科技股份有限公司 用于治疗白血病的联合用药物及其在制备用于治疗急性髓性白血病的药物中的用途
WO2021231611A1 (en) * 2020-05-12 2021-11-18 Splash Pharmaceuticals, Inc. Methods for treating cancer using spl-108 polypeptide based on tp53 mutational status
US11717787B2 (en) * 2021-01-04 2023-08-08 Saudi Arabian Oil Company High free volume membrane for gas separation
CN113855710B (zh) * 2021-10-09 2024-02-20 施慧达药业集团(吉林)有限公司 戈氏梭菌联合肿瘤血管生成抑制剂的应用
CN115350145A (zh) * 2022-09-06 2022-11-18 华中科技大学同济医学院附属协和医院 细菌介导负载二甲双胍的多肽水凝胶在肿瘤免疫治疗中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599331A (en) 1984-12-24 1986-07-08 Syntex (U.S.A.) Inc. Etianic acids as antiangiogenics
WO1987002672A1 (en) 1985-10-23 1987-05-07 The Upjohn Company Tetrahydro angiostatic steroids
US4771042A (en) 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
AU5640390A (en) 1989-06-16 1991-01-08 Upjohn Company, The Suramin type compounds and angiostatic steroids to inhibit angiogenesis
EP1236470A3 (en) 1991-11-22 2004-09-01 Alcon Laboratories, Inc. Angiostatic steroids
DE60208780T2 (de) 2001-02-28 2006-08-10 Rex Medical, L.P. Vorrichtung zur applikation von ablationsfluid zur behandlung von läsionen
WO2003045153A1 (en) * 2001-11-21 2003-06-05 The Johns Hopkins University Combination bacteriolytic therapy for the treatment of tumors
WO2005018332A1 (en) 2003-08-13 2005-03-03 The General Hospital Corporation Modified microorganisms for anti-cancer therapy
DE602004025834D1 (de) 2003-10-22 2010-04-15 Univ Johns Hopkins Die behandlung von tumoren
US20070015738A1 (en) * 2005-07-15 2007-01-18 Walker Stephen G Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid

Also Published As

Publication number Publication date
ZA201507412B (en) 2018-05-30
HK1222134A1 (zh) 2017-06-23
AU2019200276B2 (en) 2020-06-11
JP7445893B2 (ja) 2024-03-08
EP2988760B1 (en) 2020-06-17
US11439669B2 (en) 2022-09-13
SG11201508071VA (en) 2015-10-29
SG10201902765VA (en) 2019-04-29
PH12015502260A1 (en) 2016-02-01
WO2014160950A1 (en) 2014-10-02
CA3206655A1 (en) 2014-10-02
EP2988760A4 (en) 2016-10-05
BR112015024621A2 (pt) 2017-07-18
CN116570628A (zh) 2023-08-11
AU2014240872A1 (en) 2015-10-22
KR20160021084A (ko) 2016-02-24
ZA201706402B (en) 2019-01-30
US10617723B2 (en) 2020-04-14
RU2015146199A (ru) 2017-05-10
EP3730146B1 (en) 2022-05-04
JP2024056012A (ja) 2024-04-19
EP4108248A1 (en) 2022-12-28
JP2016515586A (ja) 2016-05-30
JP6756609B2 (ja) 2020-09-16
JP2019011376A (ja) 2019-01-24
IL241823B (en) 2021-02-28
NZ712691A (en) 2020-01-31
DK2988760T3 (da) 2020-07-13
EP3730146A1 (en) 2020-10-28
ES2815564T3 (es) 2021-03-30
US20220378852A1 (en) 2022-12-01
AU2019200276A1 (en) 2019-02-07
EP2988760A1 (en) 2016-03-02
JP2020152734A (ja) 2020-09-24
CA2908508C (en) 2023-09-19
RU2020111670A (ru) 2020-04-13
CA2908508A1 (en) 2014-10-02
JP2022022392A (ja) 2022-02-03
BR122020006408B1 (pt) 2021-09-28
CN105451750B (zh) 2023-03-10
US20200330525A1 (en) 2020-10-22
ES2922378T3 (es) 2022-09-14
BR112015024621B1 (pt) 2021-09-28
US20160051597A1 (en) 2016-02-25
JP2017088619A (ja) 2017-05-25
CN105451750A (zh) 2016-03-30
UA120036C2 (uk) 2019-09-25
RU2718670C2 (ru) 2020-04-13
MX2015013784A (es) 2016-08-08

Similar Documents

Publication Publication Date Title
BR112015024621A8 (pt) usos de dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica compreendendo a referida dose unitária, kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano e dose unitária de unidades formadoras de colônia de c. novyi
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
EP4140487A8 (en) Combination therapy for treating cancer
SG10201902664RA (en) Combination therapy for treating cancer
WO2016025635A3 (en) Combination therapy for treating cancer
MX2015004771A (es) Metodos para tratar cancer.
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MY180311A (en) Substituted benzene compounds
IN2015DN00376A (pt)
BR112015023212A2 (pt) tratamento do câncer utilizando anticorpos que se ligam à grp78 da superfície celular
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
MX2018002344A (es) Metodo para tratar el cancer.
BR112015025025A2 (pt) composições terapêuticas e usos das mesmas
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
MX2018007823A (es) Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal.
WO2014160967A8 (en) C. novyi for the treatment of solid tumors in non-human animals
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
BR112018011965A2 (pt) método de terapia fotodinâmica (pdt) para câncer de bexiga
BR112018007889A2 (pt) composições e métodos para terapia de câncer imuno mediada

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/03/2014, OBSERVADAS AS CONDICOES LEGAIS.